{"id":37807,"date":"2023-04-17T13:52:39","date_gmt":"2023-04-17T11:52:39","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=37807"},"modified":"2023-04-18T09:43:23","modified_gmt":"2023-04-18T07:43:23","slug":"danish-biotech-weekly-week-16","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/","title":{"rendered":"Danish Biotech Weekly – Week 16"},"content":{"rendered":"\n

In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad.<\/strong> We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets right issues, etc.<\/strong><\/p>\n\n\n\n

7 of the 20 listed, Danish biotech companies have published news the past week. 12 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date.<\/strong><\/p>\n\n\n\n

\n
Registration for the Danish Biotech Weekly newsletter<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Company news the past week<\/strong><\/p>\n\n\n\n

Ascendis Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Biosergen<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Cessatech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

CS Medica<\/strong><\/a><\/p>\n\n\n\n

CS MEDICA A\/S Announces “Proof of Concept” with Successful Clinical Trial Results of CANNASEN\u00ae Pain Patch<\/em> (LINK<\/a>)<\/p>\n\n\n\n

CS MEDICA Greenlights Establishment of CANNORDIC India Pvt. Ltd. as Part of Global Expansion Strategy (LINK)<\/a><\/p>\n\n\n\n

Curasight<\/strong><\/a><\/p>\n\n\n\n

Notice of Annual General Meeting 2023 (LINK<\/a>)<\/p>\n\n\n\n

Evaxion Biotech<\/strong><\/p>\n\n\n\n

Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform (LINK)<\/a><\/p>\n\n\n\n

Expres2ion<\/strong><\/p>\n\n\n\n

Expres2ion announces final outcome of its rights issue (LINK)<\/a><\/p>\n\n\n\n

Fluoguide<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Genmab<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Gubra<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Initiator Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

IO Biotech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Pila Pharma<\/strong><\/p>\n\n\n\n

No News the past week<\/p>\n\n\n\n

Saniona<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Scandion Oncology<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

SynAct Pharma<\/strong><\/p>\n\n\n\n

SynAct Pharma publishes annual report 2022 (LINK)<\/a><\/p>\n\n\n\n

ViroGates<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

Zealand Pharma<\/strong><\/p>\n\n\n\n

Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference (LINK)<\/a><\/p>\n\n\n\n

Y-mAbs Therapeutics<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

2cureX<\/strong><\/p>\n\n\n\n

2CUREX PRESENTS PRELIMINARY Q1 2023 COMMERCIAL RESULTS (LINK)<\/a><\/p>\n\n\n\n

2CUREX HAS RECEIVED A GRANT FROM THE INNOVATION FUND DENMARK TO SUPPORT CLINICAL DEVELOPMENT OF A NOVEL INDITREAT PRODUCT (LINK)<\/a><\/p>\n\n\n\n

SELECTED CASES<\/strong><\/p>\n\n\n\n

\n
\n

Biosergen<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Curasight<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment Case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

CS Medica<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Latest study update<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

SHARE PRICE DEVELOPMENTS<\/strong><\/p>\n\n\n\n

Evaxion Biotech A\/S<\/strong> <\/strong>became the best performing Danish biotech company last week with a 36% increase after Evaxion and Pennsylvania State University published preclinical data validating their AI-platform. At the opposite end of the spectrum ViroGates A\/S<\/strong> fell 17%. Since the start of the year, most of the companies have been under pressure, while especially Saniona AB, Curasight <\/strong>and Fluoguide AB<\/strong> have performed well. Saniona has made a strong comeback after several years of downturns. This follows a possible approval for the company\u2019s weight loss lead-candidate in Mexcio, which could generate royalties for Saniona.<\/p>\n\n\n\n

Read more about Fluoguide:<\/strong><\/mark> The unique cancer treatment of the future – Today’s investment<\/a><\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets right issues, etc. 7 of the 20 listed, Danish biotech companies have […]<\/p>\n","protected":false},"author":11,"featured_media":37397,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[9,221],"tags":[],"class_list":["post-37807","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-investeringscases","category-cs-medica-en"],"acf":[],"yoast_head":"\nDanish Biotech Weekly - Week 16 | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Danish Biotech Weekly - Week 16 | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets right issues, etc. 7 of the 20 listed, Danish biotech companies have […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-17T11:52:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-18T07:43:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1015\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Danish Biotech Weekly – Week 16\",\"datePublished\":\"2023-04-17T11:52:39+00:00\",\"dateModified\":\"2023-04-18T07:43:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/\"},\"wordCount\":438,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"articleSection\":[\"All investment Cases\",\"CS Medica\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/\",\"name\":\"Danish Biotech Weekly - Week 16 | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"datePublished\":\"2023-04-17T11:52:39+00:00\",\"dateModified\":\"2023-04-18T07:43:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"width\":1015,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"All investment Cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Danish Biotech Weekly – Week 16\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Danish Biotech Weekly - Week 16 | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/","og_locale":"en_US","og_type":"article","og_title":"Danish Biotech Weekly - Week 16 | Kapital Partner A\/S","og_description":"In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets right issues, etc. 7 of the 20 listed, Danish biotech companies have […]","og_url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2023-04-17T11:52:39+00:00","article_modified_time":"2023-04-18T07:43:23+00:00","og_image":[{"width":1015,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","type":"image\/png"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Danish Biotech Weekly – Week 16","datePublished":"2023-04-17T11:52:39+00:00","dateModified":"2023-04-18T07:43:23+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/"},"wordCount":438,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","articleSection":["All investment Cases","CS Medica"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/","url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/","name":"Danish Biotech Weekly - Week 16 | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","datePublished":"2023-04-17T11:52:39+00:00","dateModified":"2023-04-18T07:43:23+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","width":1015,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly-week-16\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"All investment Cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/"},{"@type":"ListItem","position":3,"name":"Danish Biotech Weekly – Week 16"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/37807"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=37807"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/37807\/revisions"}],"predecessor-version":[{"id":37808,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/37807\/revisions\/37808"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/37397"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=37807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=37807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=37807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}